Showing results (921-930 of 967) with videos related to
Sort By:
Pageof 97
Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Journal of Gastroenterology|November 19, 2021
Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control studyKosuke Matsumoto, Satoko Ohfuji, Masanori Abe, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2021
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progressionAtsushi Hiraoka, Takashi Kumada, Takeshi Hatanaka, et al.Cancer Medicine|November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approachTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.Journal of Hepatology|July 25, 2020
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, George Papatheodoridis, Jian Sun, et al.Pageof 97